• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Saturday, June 25, 2022
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

New therapeutic agent proves more effective treatment for advanced prostate cancer

Bioengineer by Bioengineer
January 5, 2017
in Science News
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Kambiz Rahbar, M.D., Department of Nuclear Medicine, University Hospital Muenster, and Wolfgang Peter Fendler, M.D., Department of Nuclear Medicine, University Hospital Munich

Reston, Va. – A German multicenter study, initiated by the German Society of Nuclear Medicine, demonstrates that lutetium-177 (Lu-177)-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC). The study is published in the January 2017 issue of the Journal of Nuclear Medicine and is the featured article.

Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer and even more so with castration-resistant disease. This makes development of new tracers for PSMA-targeted radionuclide therapies a promising treatment approach. Prostate cancer deaths are usually the result of mCRPC, and the median survival for men with mCRPC has been less than two years.

"Previous studies with small number of patients have indicated the high potential of this new therapeutic option," explains Kambiz Rahbar, MD, University Hospital Muenster. "This study of a large number of patients at multiple healthcare facilities, however, confirms the efficacy and safety of Lu-177-PSMA-617 radioligand therapy."

At 12 therapy centers across Germany, 145 patients (median age 73 years, range 43-88) with mCRPC were treated with Lu-177-PSMA-617 between February 2014 and July 2015 with one to four therapy cycles. A total of 248 therapy cycles were performed in 145 patients. Efficacy was defined by a prostate-specific antigen (PSA) decline of 50 percent or more from baseline to at least two weeks after start of RLT. Overall, 45 percent of patients had a positive response following all therapy cycles, while 40 percent responded after a single cycle.

Some adverse side effects were noted but manageable. Hematotoxicity occurred in 18 patients: 10 percent experienced anemia; 4 percent, thrombocytopenia (low platelet count); and 3 percent, leukopenia (low white blood cell count). Dry mouth was experienced by 8 percent.

The study shows that Lu-177-PSMA-617 radioligand therapy is safe and more effective than other third-line systemic therapies for mCRPC patients. Future Phase II and III studies are needed to clarify the survival benefit of this new therapy, which is not yet FDA-approved.

"This therapeutic will provide an additional therapy option for end-stage metastasized, heavily pretreated prostate cancer patients," said Rahbar. "While already demonstrating remarkably high response rates and low toxicity, in the future it may be available at earlier stages of disease with even higher response rates and lower toxicity."

###

Authors of the article "German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients" include first authors Kambiz Rahbar, University Hospital Muenster, and Hojjat Ahmadzadehfar, University Hospital Bonn; Clemens Kratochwil and Uwe Haberkorn, University of Heidelberg; Michael Schäfers, University Hospital Muenster; Markus Essler, University Hospital Bonn; Richard P. Baum and Harshad R Kulkarani, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, Germany; Matthias Schmidt, University of Cologne; Peter Bartenstein, Ludwig-Maximilians-University Munich; Andreas Pfestroff, University of Marburg; Ulf Lützen, Marlies Marx, Vikas Prasad and Winfried Brenner, University Hospital Berlin; Alexander Heinzel, University Hospital Aachen; Juri Ruf and Philipp Tobias Meyer, University of Freiburg; Martin Heuschkel, University of Rostock; Maria Eveslage and Martin Bögemann, University of Muenster; and senior authors Wolfgang Peter Fendler, Ludwig-Maximilians-University Munich, and Bernd Joachim Krause, University of Rostock and German Society of Nuclear Medicine, Göttingen, Germany.

Please visit the SNMMI Media Center to view the PDF of the study, including images, and more information about molecular imaging and personalized medicine. To schedule an interview with the researchers, please contact Laurie Callahan at (703) 652-6773 or [email protected] Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.

About the Society of Nuclear Medicine and Molecular Imaging

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.

SNMMI's more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www.snmmi.org.

Media Contact

Laurie Callahan
[email protected]
@SNM_MI

http://www.snm.org

############

Story Source: Materials provided by Scienmag

Share12Tweet7Share2ShareShareShare1

Related Posts

“Whisker” of crystal growing out from a crystalline front.

Scientists unravel mysterious mechanism behind “whisker crystal” growth

June 25, 2022
Smoke plume from the Riverside Fire on Mount Hood National Forest, Oregon, in September 2020

New study offers insight into past—and future—of west-side wildfires

June 25, 2022

Built infrastructure, hunting and climate change linked to huge migratory bird declines

June 25, 2022

Biofinder advances detection of extraterrestrial life

June 24, 2022
Please login to join discussion

POPULAR NEWS

  • Pacific whiting

    Oregon State University research finds evidence to suggest Pacific whiting skin has anti-aging properties that prevent wrinkles

    36 shares
    Share 14 Tweet 9
  • University of Miami Rosenstiel School selected for National ‘Reefense’ Initiative focusing on Florida and the Caribbean

    35 shares
    Share 14 Tweet 9
  • Saving the Mekong delta from drowning

    37 shares
    Share 15 Tweet 9
  • Sharks may be closer to the city than you think, new study finds

    34 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

VirusUrbanizationZoology/Veterinary ScienceVaccineWeather/StormsVaccinesVirologyVehiclesUniversity of WashingtonViolence/CriminalsWeaponryUrogenital System

Recent Posts

  • Scientists unravel mysterious mechanism behind “whisker crystal” growth
  • New study offers insight into past—and future—of west-side wildfires
  • Built infrastructure, hunting and climate change linked to huge migratory bird declines
  • Biofinder advances detection of extraterrestrial life
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Posting....